Skip to main content
. 2018 Feb 28;19(3):694. doi: 10.3390/ijms19030694

Table 1.

Summary of the most significant global effects of foods and food products containing ETs and ANCs on biomarkers of cardiometabolic risk.

SDM (p-Value) 95% CI n NT I2 (%) GRADE 1 DM (p-Value) 95% CI n NT I2 (%) GRADE
WC −0.30 (0.008) (−0.52, −0.08) 23 1023 63.4 Moderate 2 WC (cm) −1.22 (0.005) (−2.07, −0.36) 22 972 37.5 Moderate 2
T-C −0.17 (0.001) (−0.27, −0.07) 109 3991 54.5 Moderate 2 T-C (mmol/L) −0.10 (0.013) (−0.18, −0.02) 103 3673 70.6 Moderate 2
SBP −0.20 (0.000) (−0.28, −0.12) 95 3539 25.0 High SBP (mm Hg) −1.56 (0.000) (−2.13, −0.99) 83 3175 0.00 High
DBP −0.19 (0.000) (−0.26, −0.11) 99 3790 27.9 High DBP (mm Hg) −1.42 (0.000) (−2.08, −0.76) 90 3473 41.6 Moderate 2
HDL-C +0.11 (0.034) (0.01, 0.21) 99 3581 53.1 Low 2,3 HDL-C (mmol/L) +0.03 (0.062) (0.00, 0.05) 92 3239 61.6 Moderate 2
FMD +0.20 (NS) (−0.17, 0.57) 22 563 73.8 Low 2,3 FMD (%) +0.64 (0.027) (0.07, 1.20) 21 547 82.2 Low 2,3

Significant: p-value 0.05; Marginally Significant (0.05 ≤ p-value 0.1). SDM: standardized difference in means; DM: Difference in means; CI: confidence intervals; n: total number of studies; NT: total number of participants; I2: Heterogeneity Index; WC: Waist Circumference; T-C: Total Cholesterol; HDL-C: High Density Lipoprotein Cholesterol; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; FMD: Flow Mediated Dilation. 1 GRADE quality of evidence downgraded from high to moderate or low in the presence of serious risk of bias across studies and (or) serious risk of reporting bias; 2 serious risk of bias across studies: more than 50% of the studies had unclear allocation concealment, no double-blind studies and unclear reporting of dropouts; 3 serious risk of reporting bias: Eggert p-value 0.05 and more than 50% of small studies with limited number of participants.